Alnylam Pharmaceuticals saw a 13% share price increase in the last quarter, propelled by the FDA approval of Qfitlia™ for hemophilia A or B, a significant milestone reflecting its leadership in RNAi therapeutics. Despite broader market declines due to renewed tariff concerns impacting sectors like auto, Alnylam's R&D advancements and robust earnings report, showing nearly 35% growth in revenue, likely contributed to the stock's positive performance. The company's strategic objectives, partnership with Sanofi, and clear future growth avenues further solidify its competitive positioning amidst global economic uncertainties.

Buy, Hold or Sell Alnylam Pharmaceuticals? View our complete analysis and fair value estimate and you decide.

Uncover 13 companies that survived and thrived after COVID and have the right ingredients to survive Trump's tariffs.

Over the past five years, Alnylam Pharmaceuticals experienced a 153.69% total shareholder return, underscoring its ability to innovate in the biopharmaceutical sector. Notable milestones include the FDA approvals of key therapeutics such as Qfitlia™ for hemophilia and Vutrisiran's valuable expansion into treating ATTR amyloidosis. Collectively, these approvals signify Alnylam's strength in RNAi therapeutics and have been pivotal in elevating its market presence. The company’s robust R&D pipeline, which features promising advancements like the TRITON Phase 3 for nucresiran, indicates a commitment to sustainable innovation and potential revenue growth.

Financially, Alnylam's trajectory over recent years has been promising, with significant revenue increases—such as reaching US$593.17 million in Q4 2024—and minimizing net losses. These gains were bolstered by meaningful collaborations across multiple therapeutic areas and preparations for several new IND applications. Alnylam has outperformed both the US Market and US Biotechs industry over the past year, ensuring its relevance and competitive edge amid growing competition and expanding payer policies.

Review our growth performance report to gain insights into Alnylam Pharmaceuticals' future.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NasdaqGS:ALNY.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com